You are here

Home » Content

PREDÎYALÎZ, HEMODİYALİZ VE SÜREKLİ AYAKTAN PERİTON DİYALİZİ HASTALARINDA ÇİFT DOZ HEPATİT B AŞISINA YANIT

RESPONSIVENESS TO HEPATITIS B VACCINE IN HEMODIALYSIS, CAPD, AND PREDIALYSIS PATIENTS BY DOUBLING THE DOSE SCHEDULING

Journal Name:

  • Türk Nefroloji, Diyaliz ve Transplantasyon Dergisi

Publication Year:

  • 1999

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
Hepatitis B vaccine is effective in producing protection against hepatitis B virus infection in uremic patients, but these patients respond less well than do the healthy. In this study, we vaccinated 29 hemodialysis patients, 11 continuous ambulatory peritoneal dialysis patients, and 15 predialysis patients. The anti-HBs antibody-seronegative patients followed a four-dose vaccination schedule (0,1,2, and 6 months) with 40 \xg DNA-recombinant hepatitis B vaccine. The rate of total seroconversion was 78%. No differences could be found between responders and nonresponders concerning dialysis type or erythropoietin therapy. In conclusion, unresponsiveness to hepatitis B vaccine in uremic patients was related to factors such as older age, male sex, the presence of HCV-infection.
Bookmark/Search this post with
Abstract (Original Language): 
Hepatitis B aşısı, üremik hastalarda antikor oluşumu konusunda etkilidir, ancak antikor yanıtı sağlıklı insanlara göre daha az olmaktadır. Bu çalışmada, 29 hemodiyaliz, 11 sürekli ayaktan periton diyalizi ve 15 prediyaliz hastası 40 g rekombinant hepatit B aşısı ile 0, 1,2 ve 6. ayda aşılandı. Total serokonversiyon oranı %78 idi. Aşı yanıtı oluşanlarla oluşmayanlar arsında dializ tipi ve eritropoietin tedavisi açısından fark yoktu. Sonuç olarak, üremik hastalarda hepatit B aşısına yanıtın ileri yaş, erkek cinsiyet ve anti-HCV pozitifliğinden olumsuz olarak etkilendiği görüldü.
FULL TEXT (PDF): 
PDF icon pdf_tndt_269.pdf
  • 4
192-194
  • Turkish

REFERENCES

References: 

1. Kurz P, Kohler H, Meuer SC, Hutteroth T, Meyer Kh. Impaired cellular immune response to hepatitis B vaccine in chronic renal failure: Evidence for AT cell defect. Kidney Int 1986; 29: 1209-1214
2.
Gündü
z Z, Düşünsel R, Patıroğlu T, Utaş C, Kılıç H. Kronik hemodiyaliz hastalarında hepatit-B aşı uygulaması ve immün cevabın değerlendirilmesi. Türk Nefroloji Diyaliz ve Transplantasyon Dergisi 1995; 4: 25-32. '
3. Buti M, Viladamin L, Jardi R. Long term immunogenecity and efficacy of hepatitis B vaccine in hemodialysis patients. Am J Nephrol 1992; 12: 144-147
4. Dumann H, Meuer S, Meyer KH, Kohler H. Hepatit B vaccination and interleukin 2 receptor expression in
chronic renal failure. Kidney Int 1990; 38: 1164-1168
5. Egea E, Iglesias A, Salazar M, et al. The cellular basis for lack of antibody response to hepatitis B vaccine in humans. J Exp Med 1991; 173:531-538
6. Quiroga JA, Castillo I, Porres JC, Casado S, Saez F : Recombinan -interferon as adjuvant to hepatitis B vaccine in haemodialysis patients. Hepatology 1990; 12:661-663
7. Dumann H, Meuer SC, Renschin G, Köhler H. Influence of thymopentin on antibody response, monocyte and T cell function in haemodialysis patients who fail to respond to hepatitis B vaccination. Nephron 1990; 55: 136-140
8. Sennedel JJ, et al: Treatment with recombinant human erythropoietin increases antibody titer after hepatitis B vaccination in dialysis patients. Kidney Int 1991; 40: 121-128
9. Propst T, Propst A, Lhotta K, Vogcl W, König P. Reinforced intradermal hepatitis B vaccination in hemodialysis patients is superior in antibody response to intramuscular or subcutaneous vaccination. Am J
Kidney Dis 1998;32:1041-1045
10. Tokahashi H: Identification of low level hepatitis B viral genome in hepatitis B vaccine non-responders in Japan; In Hollinger FB,et al(eds). Viral Hepatitis and Liver Disease. Baltimore, Williams and Wilkins, 1990,
pp779-781.
11. Mitwalli A. Responsiveness to hepatitis B vaccine in immunocompromised patients by doubling the dose
scheduling. Nephron 1996; 73: 417-420
12. Peces R, Torre M, Alcazar R, Urra JM: Prospective analysis of the factors influencing the antibody response to hepatitis B vaccine in hemodialysis patients. Am J
Kid Dis 1997;29:239-245
13. Navarro JF, Teruel JL, Mateos M, Ortuno J. Hepatitis C virus enfection decreases the effective antibody response to hepatitis B vaccine in the hemodialysis
patients. Clin Nephrol 1994; 41: 113-116

Thank you for copying data from http://www.arastirmax.com